Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers

Cancer

Volumn 117, Issue 14, 2011, Pages 3093-3100

  Lee, Larissa J ^a,b   Alexander, Brian ^a,b   Schnitt, Stuart J ^b,c   Comander, Amy ^b,c   Gallagher, Bridget ^c   Garber, Judy E ^b,d   Tung, Nadine ^b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

BRCA1; breast cancer; chemotherapy; prognosis; triple negative

Indexed keywords

ALKYLATING AGENT; BRCA1 PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; LEUPRORELIN; METHOTREXATE; PACLITAXEL; TAMOXIFEN;

ADULT; AGED; ALLOPATHY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DNA REPAIR; FEMALE; GENE MUTATION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; ONCOGENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENES, BRCA1; HETEROZYGOTE; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROGNOSIS; RECURRENCE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79959939609     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25911     Document Type: Article

References (37)

1. Schneider BP, Winer EP, Foulkes WD, et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008; 14: 8010-8018.
2. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13 (pt 1): 4429-4434. (Pubitemid 47219710)
3. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008; 26: 1275-1281.
4. Hicks DG, Short SM, Prescott NL, et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol. 2006; 30: 1097-1104. (Pubitemid 44299342)
5. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP., Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008; 113: 2638-2645.
6. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010; 28: 3271-3277.
7. Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006; 24: 5652-5657. (Pubitemid 46631305)
8. Atchley DP, Albarracin CT, Lopez A, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008; 26: 4282-4288.
9. Musolino A, Bella MA, Bortesi B, et al. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study. Breast. 2007; 16: 280-292. (Pubitemid 46796852)
10. Turner N, Tutt A, Ashworth A., Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer. 2004; 4: 814-819. (Pubitemid 39331153)
11. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet. 1997; 349: 1505-1510.
12. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002; 20: 2310-2318. (Pubitemid 34441658)
13. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003; 100: 8418-8423. (Pubitemid 36842560)
14. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004; 10: 5367-5374. (Pubitemid 39100473)
15. Turner NC, Reis-Filho JS, Russell AM, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene. 2007; 26: 2126-2132. (Pubitemid 46514749)
16. Turner NC, Reis-Filho JS., Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006; 25: 5846-5853. (Pubitemid 44453440)
17. Collins LC, Martyniak A, Kandel MJ, et al. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. Am J Surg Pathol. 2009; 33: 1093-1097.
18. Rennert G, Bisland-Naggan S, Barnett-Griness O, Bar-Joseph N, Zhang S, Rennert HS, et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med. 2007; 357: 115-123. (Pubitemid 47057729)
19. Robson M, Levin D, Federici M, et al. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst. 1999; 91: 2112-2117. (Pubitemid 30019573)
20. El-Tamer M, Russo D, Troxel A, et al. Survival and recurrence after breast cancer in BRCA1/2 mutation carriers. Ann Surg Oncol. 2004; 11: 157-164. (Pubitemid 40486790)
21. Robson ME, Chappuis PO, Satagopan J, et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res. 2004; 6: R8-R17.
22. Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, et al. Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol. 2000; 18: 4053-4059. (Pubitemid 32038397)
23. Brekelmans CT, Seynaeve C, Menke-Pluymers M, et al. Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol. 2006; 17: 391-400. (Pubitemid 43329574)
24. Robson M, Gilewski T, Haas B, et al. BRCA-associated breast cancer in young women. J Clin Oncol. 1998; 16: 1642-1649.
25. Chappuis PO, Kapusta L, Begin LR, et al. Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer. J Clin Oncol. 2000; 18: 4045-4052. (Pubitemid 32038396)
26. Veronesi A, de Giacomi C, Magri MD, et al. Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases. BMC Cancer. 2005; 5: 70.
27. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747-752.
28. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001; 98: 10869-10874. (Pubitemid 32878711)
29. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO., Prognostic markers in triple-negative breast cancer. Cancer. 2007; 109: 25-32. (Pubitemid 46120191)
30. Tischkowitz M, Brunet JS, Begin LR, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 2007; 7: 134.
31. Calza S, Hall P, Auer G, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res. 2006; 8: R34.
32. Rakha EA, Elsheikh SE, Aleskandarany MA, et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res. 2009; 15: 2302-2310.
33. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008; 14: 1368-1376. (Pubitemid 351413917)
34. Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010; 28: 375-379.
35. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009; 361: 123-134.
36. Gronwald JBT, Huzarski T, Dent R, et al. Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. J Clin Oncol. 2009;(suppl; abstr 502) 27 (15s).
37. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010; 376: 235-244.